Zai Lab Shares Climb Over 4% on Partnership with Boehringer Ingelheim for Novel Dual DLL3-Targeting Combination Therapy

Stock News04-16

Zai Lab (09688) rose more than 4%, and as of the latest update, the stock was up 3.84% to HK$18.1, with a turnover of HK$82.7149 million. On April 15, Zai Lab announced a clinical collaboration with Boehringer Ingelheim to develop an innovative combination therapy targeting DLL3. The Ib/II phase study will evaluate the safety, tolerability, and preliminary clinical activity of Zai Lab’s DLL3-targeting ADC zocilurtatug pelitecan (zoci, formerly ZL-1310) in combination with Boehringer Ingelheim’s DLL3/CD3 T-cell engager obrixtamig. Zocilurtatug pelitecan (zoci) is a DLL3-targeting ADC developed by Zai Lab, designed to deliver a potent cytotoxic payload to DLL3-positive tumor cells for the treatment of extensive-stage small cell lung cancer (ES-SCLC). Recent global Phase I results showed that zoci demonstrated potent and durable responses in previously treated ES-SCLC patients, including those with brain metastases, along with a favorable safety profile. Based on these findings, the program has advanced into a global Phase III registrational study.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145429677?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145429677","market":"fut","top_or_hot":-1,"title":"Zai Lab Shares Climb Over 4% on Partnership with Boehringer Ingelheim for Novel Dual DLL3-Targeting Combination Therapy","media":"Stock News","content":"<p>Zai Lab (09688) rose more than 4%, and as of the latest update, the stock was up 3.84% to HK$18.1, with a turnover of HK$82.7149 million. On April 15, Zai Lab announced a clinical collaboration with Boehringer Ingelheim to develop an innovative combination therapy targeting DLL3. The Ib/II phase study will evaluate the safety, tolerability, and preliminary clinical activity of Zai Lab’s DLL3-targeting ADC zocilurtatug pelitecan (zoci, formerly ZL-1310) in combination with Boehringer Ingelheim’s DLL3/CD3 T-cell engager obrixtamig. Zocilurtatug pelitecan (zoci) is a DLL3-targeting ADC developed by Zai Lab, designed to deliver a potent cytotoxic payload to DLL3-positive tumor cells for the treatment of extensive-stage small cell lung cancer (ES-SCLC). Recent global Phase I results showed that zoci demonstrated potent and durable responses in previously treated ES-SCLC patients, including those with brain metastases, along with a favorable safety profile. Based on these findings, the program has advanced into a global Phase III registrational study.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zai Lab Shares Climb Over 4% on Partnership with Boehringer Ingelheim for Novel Dual DLL3-Targeting Combination Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZai Lab Shares Climb Over 4% on Partnership with Boehringer Ingelheim for Novel Dual DLL3-Targeting Combination Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-16 10:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zai Lab (09688) rose more than 4%, and as of the latest update, the stock was up 3.84% to HK$18.1, with a turnover of HK$82.7149 million. On April 15, Zai Lab announced a clinical collaboration with Boehringer Ingelheim to develop an innovative combination therapy targeting DLL3. The Ib/II phase study will evaluate the safety, tolerability, and preliminary clinical activity of Zai Lab’s DLL3-targeting ADC zocilurtatug pelitecan (zoci, formerly ZL-1310) in combination with Boehringer Ingelheim’s DLL3/CD3 T-cell engager obrixtamig. Zocilurtatug pelitecan (zoci) is a DLL3-targeting ADC developed by Zai Lab, designed to deliver a potent cytotoxic payload to DLL3-positive tumor cells for the treatment of extensive-stage small cell lung cancer (ES-SCLC). Recent global Phase I results showed that zoci demonstrated potent and durable responses in previously treated ES-SCLC patients, including those with brain metastases, along with a favorable safety profile. Based on these findings, the program has advanced into a global Phase III registrational study.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1145429677","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145429677","pubTimestamp":1776305660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zai Lab (09688) rose more than 4%, and as of the latest update, the stock was up 3.84% to HK$18.1, with a turnover of HK$82.7149 million. On April 15, Zai Lab announced a clinical collaboration with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","09688":"再鼎医药","BK1574":"生物医药B类股","BK4526":"热门中概股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4548":"巴美列捷福持仓","VXUS":"国际股票ETF-Vanguard","BK4531":"中概回港概念","BK1161":"生物科技","BK4588":"碎股","BK1588":"回港中概股","BK4585":"ETF&股票定投概念","ZLAB":"再鼎医药"},"translate_title":"再鼎医药与勃林格殷格翰合作开发新型双重DLL3靶向联合疗法，股价上涨超过4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1,"ZLAB":1,"VXUS":1},"content_text":"Zai Lab (09688) rose more than 4%, and as of the latest update, the stock was up 3.84% to HK$18.1, with a turnover of HK$82.7149 million. On April 15, Zai Lab announced a clinical collaboration with Boehringer Ingelheim to develop an innovative combination therapy targeting DLL3. The Ib/II phase study will evaluate the safety, tolerability, and preliminary clinical activity of Zai Lab’s DLL3-targeting ADC zocilurtatug pelitecan (zoci, formerly ZL-1310) in combination with Boehringer Ingelheim’s DLL3/CD3 T-cell engager obrixtamig. Zocilurtatug pelitecan (zoci) is a DLL3-targeting ADC developed by Zai Lab, designed to deliver a potent cytotoxic payload to DLL3-positive tumor cells for the treatment of extensive-stage small cell lung cancer (ES-SCLC). Recent global Phase I results showed that zoci demonstrated potent and durable responses in previously treated ES-SCLC patients, including those with brain metastases, along with a favorable safety profile. Based on these findings, the program has advanced into a global Phase III registrational study.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145429677","isCrawlerRequest":true}